Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEST-II
NCT04116112Phase 2Completed
- Sponsor
- University of Cincinnati
- Start
- Jan 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nicardipine, labetalol and hydralazine in ischemic stroke (3 arms), sponsored by University of Cincinnati. Primary endpoints: Final Infarct Volume at 36 hours and Utility-weighted Modified Rankin Score at 90 days. Started Jan 2020; status: completed.
02
Drugs
nicardipinelabetalolhydralazine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04116112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116112.